Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Patients with gastric dysplasia at risk of progression to gastric adenocarcinoma

06 Sep 2019

Gastric dysplasia (GD), specifically high-grade lesions, appears to carry an elevated risk of progression to gastric adenocarcinoma (GAC), according to the results of a meta-analysis.

Researchers searched multiple online databases for studies reporting the incidence rate of GAC among patients with GD. They used Cochran Q and I tests to evaluate heterogeneities between included studies.

Of the 1,980 records retrieved, 30 articles (61 studies) were included in the meta-analysis. Data were pooled using random-effect or fixed-effect models.

The overall pooled incidence rate of GAC in patients with GD was 40.36 (95 percent CI, 27.08–55.71; I2, 96.0 percent) cases per 1,000 person-years. Subgroup analysis defined according to the type of GD revealed the highest GAC incidence among patients with high-grade dysplasia (HGD) lesions (186.40 per 1,000 person-years, 106.63–285.60; I2, 94.6 percent). Among low-grade dysplasia (LGD) and nonclassified lesions, the corresponding incidence rates were 11.25 (3.91–21.22; I2, 89.3 percent) and 1.40 (0.00–9.71; I, 78.8 percent) per 1,000 person-years.

Of note, patients with HGD were about 16 times as likely as those with LGD lesions to progress from GD to GAC.

The current findings highlight the importance of strict management of HGD lesions to prevent GAC, as the majority of patients with GAC are diagnosed in an advanced stage, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.